Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Ophthalmic Drug

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2044611

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2044611

Glaucoma Treatment Market Insights, Competitive Landscape, and Market Forecast - 2033

PUBLISHED:
PAGES: 196 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 8495
Printable PDF & Excel (Enterprise License above 5 users)
USD 10600

Add to Cart

Description

Table of Contents

The global glaucoma treatment market is expanding steadily as healthcare systems place greater emphasis on early eye disease detection, long-term disease management, and vision preservation. Glaucoma is a progressive eye disorder that can damage the optic nerve and lead to irreversible vision loss if not diagnosed and treated in time. The global Glaucoma Treatment Market is valued at US$ 7.2 Bn in 2026 and is projected to reach US$ 10.1 Bn by 2033, growing at a CAGR of 4.80% during the forecast period. Increasing patient awareness, rising elderly populations, and wider availability of ophthalmic therapies are supporting consistent demand across hospitals, clinics, pharmacies, and surgical centers.

Market Insights

Glaucoma treatment is centered on reducing intraocular pressure and slowing disease progression. Medication remains the most widely used treatment option, especially for open angle glaucoma, which requires continuous monitoring and long-term therapy. Drug classes such as prostaglandin analogs, beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, combination drugs, cholinergic agents, and other therapies continue to support prescription demand. Liquid formulations, particularly eye drops, remain highly preferred due to ease of administration and broad physician acceptance. However, solid formulations and advanced delivery systems are gaining attention as companies work to improve adherence and reduce dosing frequency.

Drivers

The market is being driven by the growing prevalence of glaucoma among aging populations and individuals with risk factors such as diabetes, family history, and high intraocular pressure. As routine eye examinations become more common, diagnosis rates are improving, creating greater demand for both first-line and advanced treatment options. Another key driver is the need for therapies that improve patient compliance. Many patients struggle with daily eye drop use, missed doses, or side effects, encouraging demand for combination drugs, sustained-release solutions, and procedures that reduce dependence on frequent medication. The expansion of ophthalmic clinics and ambulatory surgical centers is also increasing access to laser therapy, surgery, and minimally invasive glaucoma surgery.

Business Opportunity

The glaucoma treatment market offers meaningful opportunities for pharmaceutical companies, device manufacturers, specialty clinics, and pharmacy networks. Companies that develop safer, more effective, and easier-to-use medications can strengthen their position in chronic glaucoma care. Fixed-dose combinations and innovative formulations can help reduce treatment complexity and improve patient outcomes. Surgical technology providers also have strong growth potential as minimally invasive glaucoma surgery gains wider clinical acceptance. Hospitals remain important for complex cases, while ophthalmic clinics are central to diagnosis, follow-up care, and procedure-based treatment. Online pharmacies are creating additional opportunities by improving prescription access and supporting patients who require regular refills over many years.

Region Analysis

North America is expected to remain a leading region in the glaucoma treatment market, supported by advanced eye care infrastructure, high disease awareness, established reimbursement systems, and strong adoption of innovative ophthalmic products. Europe also represents a significant market, driven by aging demographics, organized healthcare access, and growing emphasis on preventive eye screening. Asia Pacific is emerging as a fast-developing region due to its large patient population, rising healthcare spending, and expanding network of ophthalmology specialists. Growing awareness in countries across the region is encouraging earlier diagnosis and greater use of prescription therapies. Latin America and the Middle East & Africa are also witnessing gradual growth as eye care services expand, although affordability and access to specialists remain important challenges.

Key Players

The competitive environment includes global pharmaceutical companies, ophthalmology specialists, generic drug manufacturers, and surgical technology providers. Key players in the glaucoma treatment market include:

  • Alcon
  • AbbVie Inc. / Allergan
  • Novartis AG
  • Bausch + Lomb Corporation
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Santen Pharmaceutical Co., Ltd.
  • Aerie Pharmaceuticals
  • Glaukos Corporation
  • Johnson & Johnson
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Inc.
  • Nicox S.A.
  • Akorn Operating Company LLC

These companies are focusing on product development, portfolio expansion, strategic partnerships, and wider geographic reach. Innovation is expected to remain a major competitive factor as healthcare providers seek therapies that combine strong pressure control, safety, convenience, and long-term effectiveness.

Segmentation

By Disease Type

  • Open Angle Glaucoma
  • Angle Closure Glaucoma
  • Others

By Drug Class

  • Prostaglandin Analogs
  • Beta Blockers
  • Alpha Adrenergic Agonists
  • Carbonic Anhydrase Inhibitors
  • Combination Drugs
  • Cholinergic Agents
  • Others

By Treatment Type

  • Medication
  • Laser Therapy
  • Surgery
  • Minimally Invasive Glaucoma Surgery
  • Others

By Formulation

  • Liquid
  • Solid

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By End User

  • Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Glaucoma Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global Glaucoma Treatment Market Outlook, 2020 - 2033

  • 3.1. Global Glaucoma Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033
    • 3.1.1. Open Angle Glaucoma
    • 3.1.2. Angle Closure Glaucoma
    • 3.1.3. Others
  • 3.2. Global Glaucoma Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 3.2.1. Prostaglandin Analogs
    • 3.2.2. Beta Blockers
    • 3.2.3. Alpha Adrenergic Agonists
    • 3.2.4. Carbonic Anhydrase Inhibitors
    • 3.2.5. Combination Drugs
    • 3.2.6. Cholinergic Agents
    • 3.2.7. Others
  • 3.3. Global Glaucoma Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
    • 3.3.1. Medication
    • 3.3.2. Laser Therapy
    • 3.3.3. Surgery
    • 3.3.4. Minimally Invasive Glaucoma Surgery
    • 3.3.5. Others
  • 3.4. Global Glaucoma Treatment Market Outlook, by Formulation, Value (US$ Bn), 2020-2033
    • 3.4.1. Liquid
    • 3.4.2. Solid
  • 3.5. Global Glaucoma Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 3.5.1. Hospital Pharmacy
    • 3.5.2. Retail Pharmacy
    • 3.5.3. Online Pharmacy
  • 3.6. Global Glaucoma Treatment Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.6.1. North America
    • 3.6.2. Europe
    • 3.6.3. Asia Pacific
    • 3.6.4. Latin America
    • 3.6.5. Middle East & Africa

4. North America Glaucoma Treatment Market Outlook, 2020 - 2033

  • 4.1. North America Glaucoma Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033
    • 4.1.1. Open Angle Glaucoma
    • 4.1.2. Angle Closure Glaucoma
    • 4.1.3. Others
  • 4.2. North America Glaucoma Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 4.2.1. Prostaglandin Analogs
    • 4.2.2. Beta Blockers
    • 4.2.3. Alpha Adrenergic Agonists
    • 4.2.4. Carbonic Anhydrase Inhibitors
    • 4.2.5. Combination Drugs
    • 4.2.6. Cholinergic Agents
    • 4.2.7. Others
  • 4.3. North America Glaucoma Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
    • 4.3.1. Medication
    • 4.3.2. Laser Therapy
    • 4.3.3. Surgery
    • 4.3.4. Minimally Invasive Glaucoma Surgery
    • 4.3.5. Others
  • 4.4. North America Glaucoma Treatment Market Outlook, by Formulation, Value (US$ Bn), 2020-2033
    • 4.4.1. Liquid
    • 4.4.2. Solid
  • 4.5. North America Glaucoma Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 4.5.1. Hospital Pharmacy
    • 4.5.2. Retail Pharmacy
    • 4.5.3. Online Pharmacy
  • 4.6. North America Glaucoma Treatment Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.6.1. U.S. Glaucoma Treatment Market Outlook, by Disease Type, 2020-2033
    • 4.6.2. U.S. Glaucoma Treatment Market Outlook, by Drug Class, 2020-2033
    • 4.6.3. U.S. Glaucoma Treatment Market Outlook, by Treatment Type, 2020-2033
    • 4.6.4. U.S. Glaucoma Treatment Market Outlook, by Formulation, 2020-2033
    • 4.6.5. U.S. Glaucoma Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 4.6.6. Canada Glaucoma Treatment Market Outlook, by Disease Type, 2020-2033
    • 4.6.7. Canada Glaucoma Treatment Market Outlook, by Drug Class, 2020-2033
    • 4.6.8. Canada Glaucoma Treatment Market Outlook, by Treatment Type, 2020-2033
    • 4.6.9. Canada Glaucoma Treatment Market Outlook, by Formulation, 2020-2033
    • 4.6.10. Canada Glaucoma Treatment Market Outlook, by Distribution Channel, 2020-2033
  • 4.7. BPS Analysis/Market Attractiveness Analysis

5. Europe Glaucoma Treatment Market Outlook, 2020 - 2033

  • 5.1. Europe Glaucoma Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033
    • 5.1.1. Open Angle Glaucoma
    • 5.1.2. Angle Closure Glaucoma
    • 5.1.3. Others
  • 5.2. Europe Glaucoma Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 5.2.1. Prostaglandin Analogs
    • 5.2.2. Beta Blockers
    • 5.2.3. Alpha Adrenergic Agonists
    • 5.2.4. Carbonic Anhydrase Inhibitors
    • 5.2.5. Combination Drugs
    • 5.2.6. Cholinergic Agents
    • 5.2.7. Others
  • 5.3. Europe Glaucoma Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
    • 5.3.1. Medication
    • 5.3.2. Laser Therapy
    • 5.3.3. Surgery
    • 5.3.4. Minimally Invasive Glaucoma Surgery
    • 5.3.5. Others
  • 5.4. Europe Glaucoma Treatment Market Outlook, by Formulation, Value (US$ Bn), 2020-2033
    • 5.4.1. Liquid
    • 5.4.2. Solid
  • 5.5. Europe Glaucoma Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 5.5.1. Hospital Pharmacy
    • 5.5.2. Retail Pharmacy
    • 5.5.3. Online Pharmacy
  • 5.6. Europe Glaucoma Treatment Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.6.1. Germany Glaucoma Treatment Market Outlook, by Disease Type, 2020-2033
    • 5.6.2. Germany Glaucoma Treatment Market Outlook, by Drug Class, 2020-2033
    • 5.6.3. Germany Glaucoma Treatment Market Outlook, by Treatment Type, 2020-2033
    • 5.6.4. Germany Glaucoma Treatment Market Outlook, by Formulation, 2020-2033
    • 5.6.5. Germany Glaucoma Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.6. Italy Glaucoma Treatment Market Outlook, by Disease Type, 2020-2033
    • 5.6.7. Italy Glaucoma Treatment Market Outlook, by Drug Class, 2020-2033
    • 5.6.8. Italy Glaucoma Treatment Market Outlook, by Treatment Type, 2020-2033
    • 5.6.9. Italy Glaucoma Treatment Market Outlook, by Formulation, 2020-2033
    • 5.6.10. Italy Glaucoma Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.11. France Glaucoma Treatment Market Outlook, by Disease Type, 2020-2033
    • 5.6.12. France Glaucoma Treatment Market Outlook, by Drug Class, 2020-2033
    • 5.6.13. France Glaucoma Treatment Market Outlook, by Treatment Type, 2020-2033
    • 5.6.14. France Glaucoma Treatment Market Outlook, by Formulation, 2020-2033
    • 5.6.15. France Glaucoma Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.16. U.K. Glaucoma Treatment Market Outlook, by Disease Type, 2020-2033
    • 5.6.17. U.K. Glaucoma Treatment Market Outlook, by Drug Class, 2020-2033
    • 5.6.18. U.K. Glaucoma Treatment Market Outlook, by Treatment Type, 2020-2033
    • 5.6.19. U.K. Glaucoma Treatment Market Outlook, by Formulation, 2020-2033
    • 5.6.20. U.K. Glaucoma Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.21. Spain Glaucoma Treatment Market Outlook, by Disease Type, 2020-2033
    • 5.6.22. Spain Glaucoma Treatment Market Outlook, by Drug Class, 2020-2033
    • 5.6.23. Spain Glaucoma Treatment Market Outlook, by Treatment Type, 2020-2033
    • 5.6.24. Spain Glaucoma Treatment Market Outlook, by Formulation, 2020-2033
    • 5.6.25. Spain Glaucoma Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.26. Russia Glaucoma Treatment Market Outlook, by Disease Type, 2020-2033
    • 5.6.27. Russia Glaucoma Treatment Market Outlook, by Drug Class, 2020-2033
    • 5.6.28. Russia Glaucoma Treatment Market Outlook, by Treatment Type, 2020-2033
    • 5.6.29. Russia Glaucoma Treatment Market Outlook, by Formulation, 2020-2033
    • 5.6.30. Russia Glaucoma Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.31. Rest of Europe Glaucoma Treatment Market Outlook, by Disease Type, 2020-2033
    • 5.6.32. Rest of Europe Glaucoma Treatment Market Outlook, by Drug Class, 2020-2033
    • 5.6.33. Rest of Europe Glaucoma Treatment Market Outlook, by Treatment Type, 2020-2033
    • 5.6.34. Rest of Europe Glaucoma Treatment Market Outlook, by Formulation, 2020-2033
    • 5.6.35. Rest of Europe Glaucoma Treatment Market Outlook, by Distribution Channel, 2020-2033
  • 5.7. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Glaucoma Treatment Market Outlook, 2020 - 2033

  • 6.1. Asia Pacific Glaucoma Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033
    • 6.1.1. Open Angle Glaucoma
    • 6.1.2. Angle Closure Glaucoma
    • 6.1.3. Others
  • 6.2. Asia Pacific Glaucoma Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 6.2.1. Prostaglandin Analogs
    • 6.2.2. Beta Blockers
    • 6.2.3. Alpha Adrenergic Agonists
    • 6.2.4. Carbonic Anhydrase Inhibitors
    • 6.2.5. Combination Drugs
    • 6.2.6. Cholinergic Agents
    • 6.2.7. Others
  • 6.3. Asia Pacific Glaucoma Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
    • 6.3.1. Medication
    • 6.3.2. Laser Therapy
    • 6.3.3. Surgery
    • 6.3.4. Minimally Invasive Glaucoma Surgery
    • 6.3.5. Others
  • 6.4. Asia Pacific Glaucoma Treatment Market Outlook, by Formulation, Value (US$ Bn), 2020-2033
    • 6.4.1. Liquid
    • 6.4.2. Solid
  • 6.5. Asia Pacific Glaucoma Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 6.5.1. Hospital Pharmacy
    • 6.5.2. Retail Pharmacy
    • 6.5.3. Online Pharmacy
  • 6.6. Asia Pacific Glaucoma Treatment Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.6.1. China Glaucoma Treatment Market Outlook, by Disease Type, 2020-2033
    • 6.6.2. China Glaucoma Treatment Market Outlook, by Drug Class, 2020-2033
    • 6.6.3. China Glaucoma Treatment Market Outlook, by Treatment Type, 2020-2033
    • 6.6.4. China Glaucoma Treatment Market Outlook, by Formulation, 2020-2033
    • 6.6.5. China Glaucoma Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.6. Japan Glaucoma Treatment Market Outlook, by Disease Type, 2020-2033
    • 6.6.7. Japan Glaucoma Treatment Market Outlook, by Drug Class, 2020-2033
    • 6.6.8. Japan Glaucoma Treatment Market Outlook, by Treatment Type, 2020-2033
    • 6.6.9. Japan Glaucoma Treatment Market Outlook, by Formulation, 2020-2033
    • 6.6.10. Japan Glaucoma Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.11. South Korea Glaucoma Treatment Market Outlook, by Disease Type, 2020-2033
    • 6.6.12. South Korea Glaucoma Treatment Market Outlook, by Drug Class, 2020-2033
    • 6.6.13. South Korea Glaucoma Treatment Market Outlook, by Treatment Type, 2020-2033
    • 6.6.14. South Korea Glaucoma Treatment Market Outlook, by Formulation, 2020-2033
    • 6.6.15. South Korea Glaucoma Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.16. India Glaucoma Treatment Market Outlook, by Disease Type, 2020-2033
    • 6.6.17. India Glaucoma Treatment Market Outlook, by Drug Class, 2020-2033
    • 6.6.18. India Glaucoma Treatment Market Outlook, by Treatment Type, 2020-2033
    • 6.6.19. India Glaucoma Treatment Market Outlook, by Formulation, 2020-2033
    • 6.6.20. India Glaucoma Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.21. Southeast Asia Glaucoma Treatment Market Outlook, by Disease Type, 2020-2033
    • 6.6.22. Southeast Asia Glaucoma Treatment Market Outlook, by Drug Class, 2020-2033
    • 6.6.23. Southeast Asia Glaucoma Treatment Market Outlook, by Treatment Type, 2020-2033
    • 6.6.24. Southeast Asia Glaucoma Treatment Market Outlook, by Formulation, 2020-2033
    • 6.6.25. Southeast Asia Glaucoma Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.26. Rest of SAO Glaucoma Treatment Market Outlook, by Disease Type, 2020-2033
    • 6.6.27. Rest of SAO Glaucoma Treatment Market Outlook, by Drug Class, 2020-2033
    • 6.6.28. Rest of SAO Glaucoma Treatment Market Outlook, by Treatment Type, 2020-2033
    • 6.6.29. Rest of SAO Glaucoma Treatment Market Outlook, by Formulation, 2020-2033
    • 6.6.30. Rest of SAO Glaucoma Treatment Market Outlook, by Distribution Channel, 2020-2033
  • 6.7. BPS Analysis/Market Attractiveness Analysis

7. Latin America Glaucoma Treatment Market Outlook, 2020 - 2033

  • 7.1. Latin America Glaucoma Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033
    • 7.1.1. Open Angle Glaucoma
    • 7.1.2. Angle Closure Glaucoma
    • 7.1.3. Others
  • 7.2. Latin America Glaucoma Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 7.2.1. Prostaglandin Analogs
    • 7.2.2. Beta Blockers
    • 7.2.3. Alpha Adrenergic Agonists
    • 7.2.4. Carbonic Anhydrase Inhibitors
    • 7.2.5. Combination Drugs
    • 7.2.6. Cholinergic Agents
    • 7.2.7. Others
  • 7.3. Latin America Glaucoma Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
    • 7.3.1. Medication
    • 7.3.2. Laser Therapy
    • 7.3.3. Surgery
    • 7.3.4. Minimally Invasive Glaucoma Surgery
    • 7.3.5. Others
  • 7.4. Latin America Glaucoma Treatment Market Outlook, by Formulation, Value (US$ Bn), 2020-2033
    • 7.4.1. Liquid
    • 7.4.2. Solid
  • 7.5. Latin America Glaucoma Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 7.5.1. Hospital Pharmacy
    • 7.5.2. Retail Pharmacy
    • 7.5.3. Online Pharmacy
  • 7.6. Latin America Glaucoma Treatment Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.6.1. Brazil Glaucoma Treatment Market Outlook, by Disease Type, 2020-2033
    • 7.6.2. Brazil Glaucoma Treatment Market Outlook, by Drug Class, 2020-2033
    • 7.6.3. Brazil Glaucoma Treatment Market Outlook, by Treatment Type, 2020-2033
    • 7.6.4. Brazil Glaucoma Treatment Market Outlook, by Formulation, 2020-2033
    • 7.6.5. Brazil Glaucoma Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 7.6.6. Mexico Glaucoma Treatment Market Outlook, by Disease Type, 2020-2033
    • 7.6.7. Mexico Glaucoma Treatment Market Outlook, by Drug Class, 2020-2033
    • 7.6.8. Mexico Glaucoma Treatment Market Outlook, by Treatment Type, 2020-2033
    • 7.6.9. Mexico Glaucoma Treatment Market Outlook, by Formulation, 2020-2033
    • 7.6.10. Mexico Glaucoma Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 7.6.11. Argentina Glaucoma Treatment Market Outlook, by Disease Type, 2020-2033
    • 7.6.12. Argentina Glaucoma Treatment Market Outlook, by Drug Class, 2020-2033
    • 7.6.13. Argentina Glaucoma Treatment Market Outlook, by Treatment Type, 2020-2033
    • 7.6.14. Argentina Glaucoma Treatment Market Outlook, by Formulation, 2020-2033
    • 7.6.15. Argentina Glaucoma Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 7.6.16. Rest of LATAM Glaucoma Treatment Market Outlook, by Disease Type, 2020-2033
    • 7.6.17. Rest of LATAM Glaucoma Treatment Market Outlook, by Drug Class, 2020-2033
    • 7.6.18. Rest of LATAM Glaucoma Treatment Market Outlook, by Treatment Type, 2020-2033
    • 7.6.19. Rest of LATAM Glaucoma Treatment Market Outlook, by Formulation, 2020-2033
    • 7.6.20. Rest of LATAM Glaucoma Treatment Market Outlook, by Distribution Channel, 2020-2033
  • 7.7. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Glaucoma Treatment Market Outlook, 2020 - 2033

  • 8.1. Middle East & Africa Glaucoma Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033
    • 8.1.1. Open Angle Glaucoma
    • 8.1.2. Angle Closure Glaucoma
    • 8.1.3. Others
  • 8.2. Middle East & Africa Glaucoma Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 8.2.1. Prostaglandin Analogs
    • 8.2.2. Beta Blockers
    • 8.2.3. Alpha Adrenergic Agonists
    • 8.2.4. Carbonic Anhydrase Inhibitors
    • 8.2.5. Combination Drugs
    • 8.2.6. Cholinergic Agents
    • 8.2.7. Others
  • 8.3. Middle East & Africa Glaucoma Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
    • 8.3.1. Medication
    • 8.3.2. Laser Therapy
    • 8.3.3. Surgery
    • 8.3.4. Minimally Invasive Glaucoma Surgery
    • 8.3.5. Others
  • 8.4. Middle East & Africa Glaucoma Treatment Market Outlook, by Formulation, Value (US$ Bn), 2020-2033
    • 8.4.1. Liquid
    • 8.4.2. Solid
  • 8.5. Middle East & Africa Glaucoma Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 8.5.1. Hospital Pharmacy
    • 8.5.2. Retail Pharmacy
    • 8.5.3. Online Pharmacy
  • 8.6. Middle East & Africa Glaucoma Treatment Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.6.1. GCC Glaucoma Treatment Market Outlook, by Disease Type, 2020-2033
    • 8.6.2. GCC Glaucoma Treatment Market Outlook, by Drug Class, 2020-2033
    • 8.6.3. GCC Glaucoma Treatment Market Outlook, by Treatment Type, 2020-2033
    • 8.6.4. GCC Glaucoma Treatment Market Outlook, by Formulation, 2020-2033
    • 8.6.5. GCC Glaucoma Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 8.6.6. South Africa Glaucoma Treatment Market Outlook, by Disease Type, 2020-2033
    • 8.6.7. South Africa Glaucoma Treatment Market Outlook, by Drug Class, 2020-2033
    • 8.6.8. South Africa Glaucoma Treatment Market Outlook, by Treatment Type, 2020-2033
    • 8.6.9. South Africa Glaucoma Treatment Market Outlook, by Formulation, 2020-2033
    • 8.6.10. South Africa Glaucoma Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 8.6.11. Egypt Glaucoma Treatment Market Outlook, by Disease Type, 2020-2033
    • 8.6.12. Egypt Glaucoma Treatment Market Outlook, by Drug Class, 2020-2033
    • 8.6.13. Egypt Glaucoma Treatment Market Outlook, by Treatment Type, 2020-2033
    • 8.6.14. Egypt Glaucoma Treatment Market Outlook, by Formulation, 2020-2033
    • 8.6.15. Egypt Glaucoma Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 8.6.16. Nigeria Glaucoma Treatment Market Outlook, by Disease Type, 2020-2033
    • 8.6.17. Nigeria Glaucoma Treatment Market Outlook, by Drug Class, 2020-2033
    • 8.6.18. Nigeria Glaucoma Treatment Market Outlook, by Treatment Type, 2020-2033
    • 8.6.19. Nigeria Glaucoma Treatment Market Outlook, by Formulation, 2020-2033
    • 8.6.20. Nigeria Glaucoma Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 8.6.21. Rest of Middle East Glaucoma Treatment Market Outlook, by Disease Type, 2020-2033
    • 8.6.22. Rest of Middle East Glaucoma Treatment Market Outlook, by Drug Class, 2020-2033
    • 8.6.23. Rest of Middle East Glaucoma Treatment Market Outlook, by Treatment Type, 2020-2033
    • 8.6.24. Rest of Middle East Glaucoma Treatment Market Outlook, by Formulation, 2020-2033
    • 8.6.25. Rest of Middle East Glaucoma Treatment Market Outlook, by Distribution Channel, 2020-2033
  • 8.7. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Alcon
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. AbbVie Inc. / Allergan
    • 9.4.3. Novartis AG
    • 9.4.4. Bausch + Lomb Corporation
    • 9.4.5. Merck & Co., Inc.
    • 9.4.6. Pfizer Inc.
    • 9.4.7. Teva Pharmaceutical Industries Ltd.
    • 9.4.8. Santen Pharmaceutical Co., Ltd.
    • 9.4.9. Aerie Pharmaceuticals
    • 9.4.10. Glaukos Corporation
    • 9.4.11. Johnson & Johnson
    • 9.4.12. Sun Pharmaceutical Industries Ltd.
    • 9.4.13. Cipla Inc.
    • 9.4.14. Nicox S.A.
    • 9.4.15. Akorn Operating Company LLC

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!